Term
|
Definition
- MOA: blocks postsynaptic DA R in the mesolimbic syst & incr DA turnover by blockade of the D2 R. Decr DA-->antipsychotic effects
- USE: antipsychotic, anxiety
- TOX: Extrapyramidal effects (from D2 blockade)
-
|
|
|
Term
|
Definition
- MOA: blocks postsynaptic DA R (D2) in the mesolimbic system & Incr DA turnover by blockade of the D2 R
- USE: antipsychotic, antiemetic (DA blockade in chemoR trigger zone), HD
- TOX: hypotension, reflex tachy (blockade of a1 adrenergics), extrapyramidal effects (due toD2 blockade)
|
|
|
Term
|
Definition
- MOA: blocks D1 and D4 receptors; its effects on D2 R are relatively less than traditional antipsychotics
- USE: antipsychotic, schizophrenia
- TOX: less extrapyramidal efects bc doesn't block D2R
|
|
|
Term
|
Definition
- MOA: selective monoaminergic antagonist with a high affinity for both ST 5-HT2 and DA D2 R
- USE: antipsychotic, bipolar disorder, schizophrenia
- TOX:
|
|
|
Term
|
Definition
- MOA: partial agonist at the DA D2 and at the ST 5-HT1A R and antagonist at the ST 5-HT2AR
- USE: antipsychotic, bipolar, schizophrenia, MDD
- TOX: low CV effects, fewer extrapyramidal effects
|
|
|
